Thalidomide combined with neoadjuvant chemotherapy in angiosarcoma of the breast with complete pathologic response: case report and review of literature.
BACKGROUND
Primary angiosarcoma of the breast is a rare malignancy.


METHODS
We report on a 41-year-old female patient who initially presented with locally advanced disease. Core biopsy showed angiosarcoma of the breast, grade 1, CD31-positive. The patient was treated with neoadjuvant systemic chemotherapy based on cisplatin, doxorubicin, and paclitaxel, given concurrently with thalidomide. After treatment completion, the patient underwent radical mastectomy. Pathologic complete response in the breast and axillary lymph nodes was achieved. The patient has no evidence of disease recurrence 6 months after her initial diagnosis.


CONCLUSIONS
Anti-angiogenic therapy may be considered as part of the management of primary angiosarcoma of the breast.
Medical Oncology Department, National Cancer Institute (INCan), Mexico City, Mexico.
Alberto
A
Alvarado-Miranda
Medical Oncology Department, National Cancer Institute (INCan), Mexico City, Mexico.
Ludwing
L
Bacon-Fonseca
Medical Oncology Department, National Cancer Institute (INCan), Mexico City, Mexico.
Fernando
F
Ulises Lara-Medina
Pathology Department, National Cancer Institute (INCan), Mexico City, Mexico.
Hector
H
Maldonado-Martínez
Medical Oncology Department, National Cancer Institute (INCan), Mexico City, Mexico.
Claudia
C
Arce-Salinas
Breast angiosarcoma; Pathologic complete response; Thalidomide